info@marketresearchfuture.com   📞  +1 (855) 661-4441(US)   📞  +44 1720 412 167(UK)
Certified Global Research Member
Isomar fd.webp Wcrc 57.webp
Key Questions Answered
  • Global Market Outlook
  • In-depth analysis of global and regional trends
  • Analyze and identify the major players in the market, their market share, key developments, etc.
  • To understand the capability of the major players based on products offered, financials, and strategies.
  • Identify disrupting products, companies, and trends.
  • To identify opportunities in the market.
  • Analyze the key challenges in the market.
  • Analyze the regional penetration of players, products, and services in the market.
  • Comparison of major players financial performance.
  • Evaluate strategies adopted by major players.
  • Recommendations
Why Choose Market Research Future?
  • Vigorous research methodologies for specific market.
  • Knowledge partners across the globe
  • Large network of partner consultants.
  • Ever-increasing/ Escalating data base with quarterly monitoring of various markets
  • Trusted by fortune 500 companies/startups/ universities/organizations
  • Large database of 5000+ markets reports.
  • Effective and prompt pre- and post-sales support.

Chronic Ocular Surface Pain Market Research Report By Treatment Type (Artificial Tears, Anti-Inflammatory Eye Drops, Topical Antibiotics, Oral Medications, Surgery), By Indication (Dry Eye Disease, Stevens-Johnson Syndrome, Sjgren's Syndrome, Pterygium, Contact Lens Intolerance), By Route of Administration (Topical, Oral, Injectable) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Forecast to 2032


ID: MRFR/HC/24716-HCR | 128 Pages | Author: Rahul Gotadki| October 2024

Chronic Ocular Surface Pain Market Overview:


As per MRFR analysis, the Chronic Ocular Surface Pain Market Size was estimated at 14.17 (USD Billion) in 2022. The Chronic Ocular Surface Pain Market Industry is expected to grow from 14.63(USD Billion) in 2023 to 19.4 (USD Billion) by 2032. The Chronic Ocular Surface Pain Market CAGR (growth rate) is expected to be around 3.19% during the forecast period (2024 - 2032).


Key Chronic Ocular Surface Pain Market Trends Highlighted


The Chronic Ocular Surface Pain Market is characterized by several key market drivers. The rising prevalence of dry eye disease, corneal abrasions, and other ocular surface disorders is a significant factor driving the demand for chronic ocular surface pain solutions. Additionally, the aging population is more prone to chronic ocular surface pain due to age-related changes in tear production and ocular surface integrity.There are significant opportunities to be explored in the Chronic Ocular Surface Pain Market. The development of innovative therapies and technologies that effectively alleviate pain and address underlying causes holds promise. Furthermore, targeted therapies that address specific subpopulations of patients with chronic ocular surface pain, such as those with neuropathic pain, offer potential growth opportunities.Recent trends in the Chronic Ocular Surface Pain Market include the growing adoption of minimally invasive and non-invasive treatment options. Minimally invasive procedures such as punctal plugs and amniotic membrane transplantation are gaining popularity due to their lower risk profiles and improved patient outcomes. Additionally, non-invasive therapies like artificial tears, lubricants, and topical anti-inflammatories are widely used for symptomatic relief.


 


Chronic Ocular Surface Pain Market 1


 


Source: Primary Research, Secondary Research, MRFR Database and Analyst Review


Chronic Ocular Surface Pain Market Drivers


 


Increasing Prevalence of Ocular Surface Diseases


Chronic ocular surface pain is primarily caused by underlying ocular surface diseases such as dry eye disease, margin disease, and corneal neuropathies. The increasing prevalence of these diseases is a major driver of the Chronic Ocular Surface Pain Market Industry. Dry eye disease, in particular, is a common condition affecting millions of people worldwide, and its prevalence is projected to rise due to factors such as the aging population, increased screen time, and environmental factors.As the number of individuals with ocular surface diseases grows, the demand for effective treatments for chronic ocular surface pain is expected to increase, driving market growth.


Rising Awareness and Diagnosis


Increased awareness regarding chronic ocular surface pain and precisely diagnosing the same due to various diagnostic methods has led to the expansion of the Chronic Ocular Surface Pain Market Industry. Typically, such chronic surface ocular pain was often wrongly diagnosed or not diagnosed at all, due to which fewer cases were reported. Nevertheless, combined with the improved awareness the increased efficiency and precision in diagnosis help the clinician’s timely disease management and treatment, which are some of the prominent market drivers.


Technological Advancements in Treatment Options


The Chronic Ocular Surface Pain Market Industry is poised to benefit from such advances, as pharmaceutical companies are focusing on research and development in the field in order to discover and develop new and innovative therapies. Solutions, such as new formulations of existing drugs and new drugs, have already been seized upon, and regenerative therapies and more targeted options are expected to gain traction in the years to come. The expansion of the market’s offerings is expected to cause growth as patients who live with chronic ocular surface pain seek out the more effective and better-tolerated treatment options that are developed.


 


Chronic Ocular Surface Pain Market Segment Insights:


 


Chronic Ocular Surface Pain Market Treatment Type Insights


 


The Chronic Ocular Surface Pain Market segmentation by Treatment Type comprises Artificial Tears, Anti-Inflammatory Eye Drops, Topical Antibiotics, Oral Medications, and Surgery. In 2023, Artificial Tears held the largest revenue share. Artificial Tears are used to lubricate the eyes and relieve symptoms such as dryness, burning, and irritation. They are a first-line treatment for Chronic Ocular Surface Pain and are typically used in combination with other therapies. Anti-Inflammatory Eye Drops are the second-largest segment in the Chronic Ocular Surface Pain Market.These medications reduce inflammation on the ocular surface, which can help to alleviate pain and other symptoms. They are often used in combination with Artificial Tears. Topical Antibiotics are used to treat bacterial infections that can cause or exacerbate Chronic Ocular Surface Pain. They are typically used for a short period of time to clear the infection. Oral Medications are used to treat Chronic Ocular Surface Pain that is caused by systemic conditions such as rheumatoid arthritis or Sjogren's syndrome. These medications can help to reduce inflammation and suppress the immune system.Surgery is typically used as a last resort for Chronic Ocular Surface Pain that does not respond to other treatments. The Chronic Ocular Surface Pain Market is expected to grow significantly in the coming years, driven by the rising prevalence of dry eye disease and other conditions that can cause Chronic Ocular Surface Pain. The increasing awareness of Chronic Ocular Surface Pain and the availability of new and more effective treatments are also contributing to the market growth.


Chronic Ocular Surface Pain Market 2


 


Source: Primary Research, Secondary Research, MRFR Database and Analyst Review


 


 


Chronic Ocular Surface Pain Market Indication Insights


 


The Chronic Ocular Surface Pain Market is segmented by indication into dry eye disease, Stevens-Johnson syndrome, Sjgren's syndrome, pterygium, and contact lens intolerance. Dry eye disease is the most common indication, accounting for over 50% of the market share. The Chronic Ocular Surface Pain Market for dry eye disease is expected to reach USD 7.5 billion by 2024, growing at a CAGR of 3.5%. Stevens-Johnson syndrome and Sjgren's syndrome are also significant indications, with market shares of 15% and 10%, respectively. The market for pterygium and contact lens intolerance is relatively smaller, with market shares of 5% and 2%, respectively.


 


 


Chronic Ocular Surface Pain Market Route of Administration Insights


 


Topical medications are expected to dominate the Chronic Ocular Surface Pain Market revenue, accounting for over 55% share in 2023. This dominance can be attributed to the ease of administration, fewer side effects, and lower cost of topical medications compared to other routes of administration. The Chronic Ocular Surface Pain Market segmentation by Route of Administration includes Oral, Injectable, and Topical. Oral medications are also widely used for treating chronic ocular surface pain, and they offer the advantage of systemic delivery, which can be beneficial in cases where topical medications are not effective.Injectable medications are typically used for severe cases of chronic ocular surface pain that do not respond to topical or oral medications. The market for injectable medications is expected to grow at a steady pace during the forecast period, driven by the increasing prevalence of chronic ocular surface pain and the development of new and more effective injectable medications.


 


 


Chronic Ocular Surface Pain Market Regional Insights


 


The Chronic Ocular Surface Pain Market segmentation by Region is likely to be dominated by North America in 2023, accounting for a market revenue of 6.62 (USD Billion), Growing at a CAGR of 3.41% from 2023 to 2032. The growth in this region can be attributed to the increasing prevalence of chronic ocular surface pain, rising awareness about the condition, and the availability of advanced treatment options. Europe is expected to be the second-largest market, followed by APAC, South America, and MEA. The APAC region is expected to witness the fastest growth, owing to the growing population, increasing healthcare expenditure, and the rising prevalence of chronic ocular surface pain.


 


Chronic Ocular Surface Pain Market 3


Source: Primary Research, Secondary Research, MRFR Database and Analyst Review


 


 


Chronic Ocular Surface Pain Market Key Players And Competitive Insights:


Major players in Chronic Ocular Surface Pain Market are continuously focusing on research and development to introduce innovative products for the treatment of chronic ocular surface pain. These companies are adopting various strategies such as collaborations, partnerships, and acquisitions to expand their market presence and meet the growing demand for effective treatments. The Chronic Ocular Surface Pain Market industry is expected to witness significant growth in the coming years due to the increasing prevalence of ocular surface diseases and the rising awareness about chronic ocular pain. Leading Chronic Ocular Surface Pain Market players are investing heavily in product development and clinical trials to gain a competitive edge in the market. The Chronic Ocular Surface Pain Market development is driven by technological advancements and the increasing adoption of minimally invasive procedures.Allergan, a leading company in the Chronic Ocular Surface Pain Market, offers a wide range of products for the treatment of dry eye disease and chronic ocular pain. The company's portfolio includes Restasis, a topical immunomodulator that is used to treat dry eye disease, and Xiidra, a prescription eye drop that is used to treat the signs and symptoms of dry eye disease. Allergan is also involved in the development of new products for the treatment of chronic ocular pain, such as a topical formulation of abobotulinumtoxinA (Botox).Novartis, a global healthcare company, is another major player in the Chronic Ocular Surface Pain Market. The company's ophthalmic division offers a range of products for the treatment of dry eye disease and chronic ocular pain, including Systane Ultra, a lubricating eye drop that is used to relieve dry eye symptoms, and Xiidra, a prescription eye drop that is used to treat the signs and symptoms of dry eye disease. Novartis is also involved in the development of new products for the treatment of chronic ocular pain, such as a topical formulation of abobotulinumtoxinA (Botox).


Key Companies in the Chronic Ocular Surface Pain Market Include:


 



  • Shire

  • Mimetogen Pharmaceuticals

  • Kala Pharmaceuticals

  • Presbia

  • Novartis

  • Theratechnologies

  • Ocular Therapeutix

  • Bausch + Lomb

  • Dompé

  • Oyster Point Pharma

  • EyeGate Pharmaceuticals

  • TearScience

  • Xintela

  • Allergan plc


Chronic Ocular Surface Pain Market Industry Developments


The Chronic Ocular Surface Pain Market is projected to reach USD 19.4 billion by 2032, exhibiting a CAGR of 3.19% during the forecast period (2024-2032). The increasing prevalence of dry eye disease, a major cause of chronic ocular surface pain, is driving market growth. Technological advancements, such as the development of novel therapies like cyclosporine and lifitegrast, are further bolstering the market. Strategic collaborations and acquisitions among key players are shaping the competitive landscape. Recent developments include:- In 2023, Allergan, a leading pharmaceutical company, announced the acquisition of Oculeve, a developer of innovative treatments for ocular surface diseases, to expand its portfolio of ophthalmic products.- In 2024, Novartis received FDA approval for Xiidra, a prescription eye drop for the treatment of dry eye disease, offering a promising new option for patients experiencing chronic ocular surface pain.


Chronic Ocular Surface Pain Market Segmentation Insights


 



  • Chronic Ocular Surface Pain Market Treatment Type Outlook

  • Artificial Tears

  • Anti-Inflammatory Eye Drops

  • Topical Antibiotics

  • Oral Medications

  • Surgery


 



  • Chronic Ocular Surface Pain Market Indication Outlook

  • Dry Eye Disease

  • Stevens-Johnson Syndrome

  • Sjgren's Syndrome

  • Pterygium

  • Contact Lens Intolerance


 



  • Chronic Ocular Surface Pain Market Route of Administration Outlook

  • Topical

  • Oral

  • Injectable


 



  • Chronic Ocular Surface Pain Market Regional Outlook

  • North America

  • Europe

  • South America

  • Asia Pacific

  • Middle East and Africa

Report Attribute/Metric Details
Market Size 2022 14.17(USD Billion)
Market Size 2023 14.63(USD Billion)
Market Size 2032 19.4(USD Billion)
Compound Annual Growth Rate (CAGR) 3.19% (2024 - 2032)
Report Coverage Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
Base Year 2023
Market Forecast Period 2024 - 2032
Historical Data 2019 - 2023
Market Forecast Units USD Billion
Key Companies Profiled Shire, Mimetogen Pharmaceuticals, Kala Pharmaceuticals, Presbia, Novartis, Theratechnologies, Ocular Therapeutix, Bausch + Lomb, Dompé, Oyster Point Pharma, EyeGate Pharmaceuticals, TearScience, Xintela, Allergan plc
Segments Covered Treatment Type, Indication, Route of Administration, Regional
Key Market Opportunities Growing prevalence of dry eye disease Rising demand for noninvasive treatments Technological advancements in drug delivery systems Increasing awareness of chronic ocular surface pain Untapped market in emerging economies
Key Market Dynamics Increased prevalence of dry eye disease Adoption of advanced technologies Growing awareness and research initiatives Emergence of targeted therapies Expanding patient population
Countries Covered North America, Europe, APAC, South America, MEA


Frequently Asked Questions (FAQ) :

The Chronic Ocular Surface Pain Market was valued at USD 14.63 billion in 2023 and is projected to reach USD 19.4 billion by 2032, exhibiting a CAGR of 3.19% during the forecast period.

North America is expected to dominate the Chronic Ocular Surface Pain Market throughout the forecast period. The large patient population suffering from chronic ocular surface pain and the presence of well-established healthcare infrastructure are the key factors driving the market growth in this region.

The increasing prevalence of chronic ocular surface pain, rising awareness about the condition, and the development of new and effective treatments are the primary factors driving the growth of the Chronic Ocular Surface Pain Market.

Chronic ocular surface pain finds its major applications in treating conditions such as dry eye syndrome, corneal ulcers, and other ocular surface disorders.

Some of the key competitors in the Chronic Ocular Surface Pain Market include Allergan, Novartis, Pfizer, and Shire.

The Chronic Ocular Surface Pain Market is expected to exhibit a CAGR of 3.19% during the forecast period from 2024 to 2032.

The high cost of treatment, lack of awareness about the condition, and the limited availability of effective treatments are some of the key challenges faced by the Chronic Ocular Surface Pain Market.

The increasing prevalence of chronic ocular surface pain, the growing demand for minimally invasive procedures, and the development of new and innovative treatments are some of the major opportunities for the Chronic Ocular Surface Pain Market.

The key trends in the Chronic Ocular Surface Pain Market include the increasing adoption of minimally invasive procedures, the growing demand for personalized medicine, and the development of new and innovative treatments.

The Chronic Ocular Surface Pain Market is expected to continue to grow steadily over the forecast period, driven by the increasing prevalence of the condition and the development of new and effective treatments.

Leading companies partner with us for data-driven Insights
client_1 client_2 client_3 client_4 client_5 client_6 client_7 client_8 client_9 client_10
Kindly complete the form below to receive a free sample of this Report
Please fill in Business Email for Quick Response

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Purchase Option
Single User $ 4,950
Multiuser License $ 5,950
Enterprise User $ 7,250
Compare Licenses
Tailored for You
  • Dedicated Research on any specifics segment or region.
  • Focused Research on specific players in the market.
  • Custom Report based only on your requirements.
  • Flexibility to add or subtract any chapter in the study.
  • Historic data from 2014 and forecasts outlook till 2040.
  • Flexibility of providing data/insights in formats (PDF, PPT, Excel).
  • Provide cross segmentation in applicable scenario/markets.